Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

5.0K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.5K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

7.6K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.6K
Abnormal Proliferation02:23

Abnormal Proliferation

5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

7.7K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
7.7K
The Ras Gene02:38

The Ras Gene

6.9K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spatial transcriptomic analysis of mouse parathyroid gland cells expressing an activating variant of <i>Gcm2</i>.

JBMR plus·2025
Same author

Tendon-associated gene expression precedes osteogenesis in mid-palatal suture establishment.

bioRxiv : the preprint server for biology·2024
Same author

The Spectrum of GH Excess in Carney Complex and Genotype-phenotype Correlations.

The Journal of clinical endocrinology and metabolism·2024
Same author

Evidence of the Role of Inflammation and the Hormonal Environment in the Pathogenesis of Adrenal Myelolipomas in Congenital Adrenal Hyperplasia.

International journal of molecular sciences·2024
Same author

Multimodal spatiotemporal transcriptomic resolution of embryonic palate osteogenesis.

Nature communications·2023
Same author

Embryonic stem cell factor FOXD3 (Genesis) defects in gastrointestinal stromal tumors.

Endocrine-related cancer·2023

Related Experiment Video

Updated: Dec 13, 2025

Analysis of the c-KIT Ligand Promoter Using Chromatin Immunoprecipitation
09:40

Analysis of the c-KIT Ligand Promoter Using Chromatin Immunoprecipitation

Published on: June 27, 2017

8.1K

c-KIT oncogene expression in PRKAR1A-mutant adrenal cortex.

Kiran Nadella1, Fabio R Faucz1, Constantine A Stratakis1

  • 1Section on Genetics and Endocrinology (SEGEN), Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD), National Institutes of Health (NIH), Bethesda, Maryland, USA.

Endocrine-Related Cancer
|August 2, 2020
PubMed
Summary

Defects in PRKAR1A cause PPNAD. This study found KIT protooncogene (c-KIT) is expressed in PPNAD and inhibiting it slowed tumor growth, suggesting c-KIT inhibitors as a potential therapy for PPNAD.

Keywords:
PRKAR1A geneadrenocortical hyperplasiacortisolcyclic AMPtyrosine protein kinase KIT

More Related Videos

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes
15:43

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

Published on: January 7, 2013

18.5K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.4K

Related Experiment Videos

Last Updated: Dec 13, 2025

Analysis of the c-KIT Ligand Promoter Using Chromatin Immunoprecipitation
09:40

Analysis of the c-KIT Ligand Promoter Using Chromatin Immunoprecipitation

Published on: June 27, 2017

8.1K
Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes
15:43

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

Published on: January 7, 2013

18.5K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.4K

Area of Science:

  • Endocrinology
  • Oncology
  • Molecular Biology

Background:

  • Primary pigmented nodular adrenocortical disease (PPNAD) is linked to Protein Kinase A (PKA) regulatory subunit type 1A (PRKAR1A) defects.
  • The KIT protooncogene (c-KIT) and its ligand, stem cell factor (SCF), are not typically found in the normal adrenal cortex.

Purpose of the Study:

  • To investigate the expression of c-KIT and SCF in PPNAD and other cortisol-producing adrenal tumors.
  • To explore the role of PRKAR1A and PKA activity in regulating c-KIT expression.
  • To evaluate the therapeutic potential of c-KIT inhibition in PPNAD models.

Main Methods:

  • Quantitative real-time PCR (qRT-PCR) for mRNA expression.
  • Immunohistochemistry (IHC) and immunoblotting (IB) for protein expression.
  • In vitro studies using adrenocortical cell lines (CAR47, H295R) with PRKAR1A manipulation and PKA stimulation.
  • In vivo studies using imatinib mesylate (IM) treatment in mice xenografted with H295R cells.

Main Results:

  • Increased c-KIT mRNA expression was observed in PPNAD samples.
  • KIT and SCF protein immunoreactivity was detected in nodular areas of PPNAD.
  • c-KIT expression in PRKAR1A-deficient cells was enhanced by PKA stimulation and reduced by PRKAR1A reintroduction.
  • Inhibition of c-KIT with imatinib mesylate reduced cell viability, induced growth arrest, and promoted apoptosis in cell lines and inhibited tumor growth in mice xenografts.

Conclusions:

  • c-KIT is expressed in PPNAD, with its expression dependent on PRKAR1A and/or PKA activity.
  • Inhibition of c-KIT demonstrates therapeutic potential, suggesting c-KIT inhibitors as a viable treatment option for PPNAD when other therapies are suboptimal.